Essex In the News

Essex Woodlands Opens New International Office in Shanghai to Invest in Rapidly Growing Chinese Healthcare Companies

SHANGHAI, CHINA—(Marketwire - December 4, 2012) - Essex Woodlands, a leading healthcare growth capital firm with a global investment practice, announced today the opening of a new office in Shanghai, China. The Shanghai…  

NEWARK, Calif.— Revance Therapeutics, Inc. (Revance) today announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation (NYSE:MRX) concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A. As part of the settlement, all worldwide rights to develop and commercialize both…  

PINE BROOK, NJ –  Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been awarded additional funding from the U.S. Government, valued at $14.5 million, to support expanded human safety studies of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection…  

Danvers cardiac device maker Abiomed Inc. has won federal approval to sell a new heart pump that is less invasive and delivers greater blood flow than a similar model it now markets.

Abiomed said Monday that its Impella CP pump was approved by the Food and Drug Administration under the…  

COPENHAGEN, DENMARK —Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt,…